

Supplementary Table 2: Baseline characteristics of the SGLT2i 'add-on' vs the SGLT2i 'switch' cohorts prior to and after propensity score matching.

	UNMATCHED			PROPENSITY-SCORE MATCHED		
	SGLT2i 'add-on'	SGLT2i 'switch'	SMD	SGLT2i	SGLT2i	SMD
				'add-on'	'switch'	
Number of patients	7,167	4,891		4,843	4,843	
Female gender n (%)	3,088 (43.1)	2,329 (47.6)	0.091	2,192 (45.3)	2,300 (47.5)	0.045
Age at diagnosis of DM (mean (SD))	54.6 (9.1)	54.0 (9.1)	0.073	54.3 (9.1)	54.0 (9.1)	0.028
Age at index date (mean (SD))	61.0 (9.4)	60.2 (9.4)	0.079	60.5 (9.5)	60.3 (9.4)	0.030
Days on DPP4 since diagnosis (mean (SD))	1,026 (738)	967 (708)	0.082	1,000 (734)	969 (708)	0.041
Days from diagnosis to index (mean (SD))	2305 (689)	2280 (682)	0.037	2291 (689)	2282 (681)	0.014
Ratio of days (mean (SD))	0.31 (2.87)	0.22 (1.01)	0.043	0.23 (1.68)	0.22 (1.02)	0.005
Year of DM diagnosis (%)			0.059			0.056
≤ 2009	4,914 (68.6)	3,334 (68.2)		3,269 (67.5)	3,303 (68.2)	
- 2010	630 (8.8)	410 (8.4)		443 (9.1)	406 (8.4)	
- 2011	491 (6.9)	357 (7.3)		356 (7.4)	352 (7.3)	
- 2012	346 (4.8)	265 (5.4)		247 (5.1)	262 (5.4)	
- 2013	287 (4.0)	213 (4.4)		194 (4.0)	213 (4.4)	
- 2014	237 (3.3)	144 (2.9)		159 (3.3)	142 (2.9)	
- 2015	164 (2.3)	119 (2.4)		108 (2.2)	117 (2.4)	
- 2016	79 (1.1)	43 (0.9)		60 (1.2)	42 (0.9)	
- 2017	19 (0.3)	6 (0.1)		7 (0.1)	6 (0.1)	
Index year (%)			0.084			0.077

- 2014	192 (2.7)	178 (3.6)		133 (2.7)	177 (3.7)	
- 2015	1,708 (23.8)	1,270 (26.0)		1,170 (24.2)	1,251 (25.8)	
- 2016	3,176 (44.3)	2,017 (41.2)		2,147 (44.3)	1,998 (41.3)	
- 2017	2,091 (29.2)	1,426 (29.2)		1,393 (28.8)	1,417 (29.3)	
AMI with PCI n (%)	173 (2.4)	147 (3.0)	0.036	132 (2.7)	139 (2.9)	0.009
CABG surgery n (%)	92 (1.3)	44 (0.9)	0.037	58 (1.2)	44 (0.9)	0.028
PCI with stenting n (%)	341 (4.8)	263 (5.4)	0.028	248 (5.1)	255 (5.3)	0.007
Chronic heart failure n (%)	239 (3.3)	166 (3.4)	0.003	159 (3.3)	161 (3.3)	0.002
Atrial fibrillation n (%)	412 (5.7)	232 (4.7)	0.045	259 (5.3)	230 (4.7)	0.027
Stroke n (%)	265 (3.7)	155 (3.2)	0.029	166 (3.4)	155 (3.2)	0.013
Peripheral artery disease n (%)	174 (2.4)	145 (3.0)	0.033	115 (2.4)	142 (2.9)	0.035
Lower limb amputation n (%)	34 (0.5)	31 (0.6)	0.021	24 (0.5)	29 (0.6)	0.014
Cancer n (%)	480 (6.7)	328 (6.7)	<0.001	335 (6.9)	324 (6.7)	0.009
COPD n (%)	268 (3.7)	208 (4.3)	0.026	195 (4.0)	202 (4.2)	0.007
Severe hypoglycemia n (%)	<10 (0.1)	<10 (0.1)	0.010	<10 (0.1)	<10 (0.1)	<0.001
Keto-/lactic acidosis n (%)	<10 (0.0)	<10 (0.1)	0.029	<10 (0.0)	<10 (0.1)	0.020
Major bleeding n (%)	126 (1.8)	70 (1.4)	0.026	75 (1.5)	70 (1.4)	0.009
Metformin n (%)	1,600 (22.3)	1,555 (31.8)	0.214	1,263 (26.1)	1,511 (31.2)	0.113
Sulphonylurea n (%)	4,210 (58.7)	3,146 (64.3)	0.115	2,931 (60.5)	3,109 (64.2)	0.076
GLP-1RA n (%)	162 (2.3)	149 (3.0)	0.049	132 (2.7)	141 (2.9)	0.011
Metiglinides n (%)	10 (0.1)	<10 (0.1)	0.005	<10 (0.1)	<10 (0.1)	0.006
Metformin + metiglinid n (%)	40 (0.6)	17 (0.3)	0.031	25 (0.5)	17 (0.4)	0.025
Glitazones n (%)	48 (0.7)	20 (0.4)	0.036	21 (0.4)	20 (0.4)	0.003
Acarbose n (%)	389 (5.4)	167 (3.4)	0.098	224 (4.6)	167 (3.4)	0.060
Insulin n (%)	350 (4.9)	362 (7.4)	0.105	275 (5.7)	330 (6.8)	0.047

Short acting insulin (Human/analog) n (%)	87 (1.2)	100 (2.0)	0.066	77 (1.6)	88 (1.8)	0.018
Intermediate insulin (human basal) n (%)	168 (2.3)	175 (3.6)	0.073	137 (2.8)	161 (3.3)	0.029
Long acting insulin (analog basal) n (%)	184 (2.6)	177 (3.6)	0.061	141 (2.9)	161 (3.3)	0.024
Premix insulin (human/analog) n (%)	22 (0.3)	35 (0.7)	0.057	19 (0.4)	28 (0.6)	0.027
CV risk treatment n (%)	6,631 (92.5)	4,506 (92.1)	0.015	4,479 (92.5)	4,460 (92.1)	0.015
Low dose Aspirin n (%)	2,149 (30.0)	1,618 (33.1)	0.067	1,506 (31.1)	1,593 (32.9)	0.039
Statin n (%)	3,863 (53.9)	2,590 (53.0)	0.019	2,599 (53.7)	2,556 (52.8)	0.018
Antihypertensives n (%)	6,276 (87.6)	4,270 (87.3)	0.008	4,233 (87.4)	4,225 (87.2)	0.005
ACEi n (%)	4,017 (56.0)	2,797 (57.2)	0.023	2,756 (56.9)	2,767 (57.1)	0.005
ARB n (%)	2,266 (31.6)	1,407 (28.8)	0.062	1,470 (30.4)	1,397 (28.8)	0.033
Dihydropyridine CCB n (%)	1,536 (21.4)	984 (20.1)	0.032	1,022 (21.1)	977 (20.2)	0.023
Non-dihydropyridine CCB n (%)	101 (1.4)	74 (1.5)	0.009	73 (1.5)	68 (1.4)	0.009
Beta blockers n (%)	3,735 (52.1)	2,628 (53.7)	0.032	2,568 (53.0)	2,596 (53.6)	0.012
Thiazides n (%)	40 (0.6)	30 (0.6)	0.007	34 (0.7)	28 (0.6)	0.016
Loop diuretics n (%)	927 (12.9)	664 (13.6)	0.019	636 (13.1)	650 (13.4)	0.009
Aldosterone antagonist n (%)	321 (4.5)	258 (5.3)	0.037	223 (4.6)	251 (5.2)	0.027
Digoxin n (%)	119 (1.7)	72 (1.5)	0.015	77 (1.6)	70 (1.4)	0.012
Digitoxin n (%)	37 (0.5)	24 (0.5)	0.004	23 (0.5)	24 (0.5)	0.003
Amiodarone n (%)	61 (0.9)	29 (0.6)	0.031	32 (0.7)	28 (0.6)	0.011
Warfarin n (%)	141 (2.0)	85 (1.7)	0.017	91 (1.9)	84 (1.7)	0.011
P2Y12 receptor antagonists n (%)	701 (9.8)	460 (9.4)	0.013	451 (9.3)	451 (9.3)	<0.001
Factor X _A inhibitor n (%)	84 (1.2)	52 (1.1)	0.010	52 (1.1)	50 (1.0)	0.004
Direct thrombin inhibitor n (%)	39 (0.5)	19 (0.4)	0.023	25 (0.5)	19 (0.4)	0.018
Other antiplatelets n (%)	15 (0.2)	11 (0.2)	0.003	13 (0.3)	11 (0.2)	0.008
Corticosteroids n (%)	263 (3.7)	189 (3.9)	0.010	180 (3.7)	186 (3.8)	0.006
Weight loss medication n (%)	<10 (0.0)	<10 (0.0)	0.005	<10 (0.0)	<10 (0.0)	<0.001

The data include some demographic parameters (age and gender), significant co-morbidities as well as anti-diabetic and cardiovascular medications. ACEi = angiotensin-converting enzyme inhibitors, ARB = angiotensin-II receptor blockers, CCB = calcium channel blockers, CV = cardiovascular, SMD = standardized mean difference
